Comparison of Efficacy and Safety of Albumin Versus Fresh Frozen Plasma in Managing Diuretic Resistant Edema in Children With Idiopathic Nephrotic Syndrome. (ALB-FFP)
Comparison of Efficacy and Safety of Albumin Versus Fresh Frozen Plasma in Managing Diuretic Resistant Edema in Children With Idiopathic Nephrotic Syndrome
Edema is a major component of nephrotic syndrome (NS), defined by Kidney Disease Improving Global Outcomes (KDIGO) guidelines is, urine protein/creatinine ratio ≥ 2 mg/mg, and hypoalbuminemia ≤ 2.5 g/dl). The causes of diuretic resistance include poor adherence to drug therapy or diet, pharmacokinetic issues, and compensatory sodium reabsorption. Impaired tubular secretion of diuretics is a common cause of diuretic resistance. The cornerstone of managing diuretic resistance is breaking the pathophysiological cycle. Fresh Frozen Plasma (FFP) is a viable, cost-effective alternative to intravenous albumin for managing diuretic resistant edema in children with idiopathic nephrotic syndrome (INS) but it may require more infusions than albumin.
The main purpose of the study is to compare the albumin versus fresh frozen plasma in managing diuretic resistant edema in children with idiopathic nephrotic syndrome The duration of study is six months after approval of synopsis. The study will be conducted in indoor Department of pediatric nephrology department, The Children's Hospital & the Institute of Child Health, Multan. A sample size of 56 patients will be included in the study. Informed consent will be taken from included patients. The Group-A study population will be with intravenous albumin, 1 gm/kg/day in single daily dose over 4 hours followed by intravenous furosemide 1 mg/kg/day. Salt poor 20% human albumin will be administered which will be osmotically equivalent to 200ml of plasma. The Group-B study population will be with intravenous FFP 15ml/kg/day over 2 hours followed by intravenous furosemide 1 mg/kg. Primary outcomes will be response to treatment in form of resolution of clinical signs within 72 hours of treatment. Secondary outcomes will be duration of hospital stay, mortality, complication of treatment, complications of disease and hearing assessment.
Data will be analyzed through SPSS v23. For quantitative variables, the mean standard deviation will be calculated and for qualitative variables, frequency and percentage will be calculated. This study will provide a better opportunity to study Albumin versus fresh frozen plasma in managing diuretic resistant edema in children with idiopathic nephrotic syndrome in The Children's Hospital & the Institute of Child Health, Multan
研究概览
详细说明
Edema is a major component of nephrotic syndrome (NS), defined by Kidney Disease Improving Global Outcomes (KDIGO) guidelines is, urine protein/creatinine ratio ≥ 2 mg/mg, and hypoalbuminemia ≤ 2.5 g/dl). Nephrotic syndrome is one of the most common pediatric renal diseases with an annual incidence of 1.2-16.9/100,000 children. It is characterized by edema, massive proteinuria (>40 mg/m2/h), and hypoalbuminemia (serum albumin <3 g/dL)(Kallash & Mahan, 2021). Edema affects the quality of life of pediatric patients with NS, even when it is only mild to moderate in severity, and this is especially seen in patients with steroid resistant NS. Albumin infusions can be a highly effective method to treat edema in patients with NS. Edema can develop in nephrotic syndrome, chronic kidney disease (CKD), heart failure, and liver cirrhosis. Usually, the patients with edema respond to dietary sodium restriction in combination with a loop diuretic. However, some patients become resistant to diuretics. Diuretic resistance is defined as the failure to achieve the therapeutically desired reduction in edema even when a maximal dose of diuretic is employed (Hoorn & Ellison, 2017).
The causes of diuretic resistance include poor adherence to drug therapy or diet, pharmacokinetic issues, and compensatory sodium reabsorption. Impaired tubular secretion of diuretics is a common cause of diuretic resistance. The cornerstone of managing diuretic resistance is breaking the pathophysiological cycle (Bell & Mandalia, 2022). First-line management of edema involves sodium restriction and oral diuretics, most commonly loop diuretics like furosemide. However, a state of diuretic resistance often develops. This resistance is primarily due to two reasons reduced delivery: The hypoalbuminemia reduces the transport of furosemide to its site of action in the nephron, as the drug is highly protein-bound. Compensatory mechanisms are the intense activation of renin-angiotensin-aldosterone system and other neurohormonal pathways counteracts the natriuretic effect of diuretics, leading to rebound sodium retention (El-Halaby et al., 2022). Fresh Frozen Plasma (FFP) is a viable, cost-effective alternative to intravenous albumin for managing diuretic resistant edema in children with idiopathic nephrotic syndrome (INS) but it may require more infusions than albumin. FFP cost half than albumin and same duration required to reduce edema but with double number of infusion and it is safe in pediatric patients with NS presenting with moderate to severe edema. The cost-effectiveness may place FFP as a better choice especially in developing countries of the world (Al Mamun et al., 2015).
Due to availability of limited local data, the aim of this randomized control trial study is to evaluate the efficacy of albumin versus fresh frozen plasma in managing diuretic resistant edema in children with idiopathic nephrotic syndrome in children's hospital and institute of child health Multan Punjab Pakistan, so that the overall morbidity and mortality due to NS can be reduced
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Qamar Shafiq, MBBS
- 电话号码:00923076960500
- 邮箱:qamarshafiq710@gmail.com
研究联系人备份
- 姓名:muhammad Asif, MBBS
- 电话号码:00923143329514
- 邮箱:asif18june@gmail.com
参与标准
资格标准
适合学习的年龄
- 孩子
接受健康志愿者
描述
Inclusion Criteria:
- Children diagnosed with an idiopathic nephrotic syndrome and diuretic resistant as per the definition • Children of either gender. • Children of 2-12 years of age
Exclusion Criteria:
- • Patients with secondary nephrotic syndrome/heart failure/hepatic dysfunction/severe renal impairment • Children with severe sepsis/hemodynamically unstable. • Children who had recent exchange transfusion • Parents refused to follow up
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:albumin
The Group-A study population will be given intravenous albumin, 1 gm/kg/day over 4 hours in single daily dose followed by intravenous furosemide 1 mg/kg/day.
Salt poor 20% human albumin will be administered which will be osmotically equivalent to 200ml of plasma.
The Group-B study population will be given intravenous FFP 15ml/kg/day over 2 hours followed by intravenous furosemide 1 mg/kg
|
The Group-A study population will be given intravenous albumin, 1 gm/kg/day over 4 hours in single daily dose followed by intravenous furosemide 1 mg/kg/day.
Salt poor 20% human albumin will be administered which will be osmotically equivalent to 200ml of plasma.
The Group-B study population will be given intravenous FFP 15ml/kg/day over 2 hours followed by intravenous furosemide 1 mg/kg
The Group-A study population will be given intravenous albumin, 1 gm/kg/day over 4 hours in single daily dose followed by intravenous furosemide 1 mg/kg/day.
Salt poor 20% human albumin will be administered which will be osmotically equivalent to 200ml of plasma.
The Group-B study population will be given intravenous FFP 15ml/kg/day over 2 hours followed by intravenous furosemide 1 mg/kg
|
|
有源比较器:fresh frozen plasma
The Group-A study population will be given intravenous albumin, 1 gm/kg/day over 4 hours in single daily dose followed by intravenous furosemide 1 mg/kg/day.
Salt poor 20% human albumin will be administered which will be osmotically equivalent to 200ml of plasma.
The Group-B study population will be given intravenous FFP 15ml/kg/day over 2 hours followed by intravenous furosemide 1 mg/kg
|
The Group-A study population will be given intravenous albumin, 1 gm/kg/day over 4 hours in single daily dose followed by intravenous furosemide 1 mg/kg/day.
Salt poor 20% human albumin will be administered which will be osmotically equivalent to 200ml of plasma.
The Group-B study population will be given intravenous FFP 15ml/kg/day over 2 hours followed by intravenous furosemide 1 mg/kg
The Group-A study population will be given intravenous albumin, 1 gm/kg/day over 4 hours in single daily dose followed by intravenous furosemide 1 mg/kg/day.
Salt poor 20% human albumin will be administered which will be osmotically equivalent to 200ml of plasma.
The Group-B study population will be given intravenous FFP 15ml/kg/day over 2 hours followed by intravenous furosemide 1 mg/kg
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
time to resolution of edema
大体时间:baselines to 72 hours post intervention
|
primary outcome is time required to achieve clinically significant resolution of edema
|
baselines to 72 hours post intervention
|
|
Primary outcomes will be response to treatment in form of resolution of clinical signs within 24 to 48 hours of treatment
大体时间:24 to 48 hours
|
Primary outcomes will be response to treatment in form of resolution of clinical signs within 24 to 48 hours of treatment
|
24 to 48 hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
change in serum albumin level
大体时间:baselines to 72 hours post intervention
|
difference in serum albumin concentration measured before and after intervention in both study groups
|
baselines to 72 hours post intervention
|
合作者和调查者
赞助
调查人员
- 首席研究员:Tariq aziz, MBBS FCPS、Children's Hospital and Institute of Child Health, Multan
出版物和有用的链接
一般刊物
- Kallash, M., & Maha
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- CHCMultan
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.